Mer­ri­mack shut­ters a fail­ing PhII breast can­cer study for MM-302

Mer­ri­mack Phar­ma­ceu­ti­cals has de­cid­ed to scrap a Phase II breast can­cer study of MM-302 for treat­ment re­sis­tant pa­tients af­ter in­ves­ti­ga­tors de­ter­mined that they were on a one-way track to a fail­ure.

Mer­ri­mack $MACK was fol­low­ing up on some pos­i­tive ear­ly re­sults from a Phase I study that re­port­ed out in April, 2015, in­di­cat­ing that it may have been help­ing HER2-pos­i­tive pa­tients who had failed mul­ti­ple treat­ments.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.